Core Viewpoint - Johnson & Johnson is positioning itself for significant growth, particularly in its oncology segment, which could make its stock an attractive investment opportunity in the coming years [2][3][4]. Financial Performance - In 2025, Johnson & Johnson reported a revenue increase of 6% to $94.2 billion, consistent with its historical growth patterns [2]. - The company anticipates revenue of $100.5 billion for 2026, reflecting a projected growth rate of approximately 6.7% [4]. Growth Potential - CEO Joaquin Duato expressed optimism about achieving double-digit growth by the end of the decade, driven largely by advancements in oncology [3]. - The oncology business is expected to generate $50 billion, doubling its previous year's performance [3]. Valuation Metrics - The stock currently trades at around 21 times its trailing earnings, with a price-to-earnings-growth (PEG) ratio of about 1.2, indicating it may not be a bargain but still presents a reasonable investment opportunity [5]. - The stock is viewed as a safe-haven investment, offering a dividend yield of 2.3%, which could enhance its attractiveness as a long-term buy [6].

Core Insights - Amgen (AMGN) reported Q4 2025 adjusted earnings of $5.29 per share, exceeding the Zacks Consensus Estimate of $4.76 per share, with total revenues of $9.9 billion, a 9% year-over-year increase, surpassing the estimate of $9.5 billion [2][7] Revenue Performance - Total product revenues increased by 7% year-over-year to $9.37 billion, with a 10% rise in volume offset by a 4% negative impact from pricing [3] - Other revenues reached $499 million, up approximately 35% year-over-year [3] Key Drug Performance - Evenity sales were $599 million, a 39% increase year-over-year, surpassing the estimate of $565 million [4] - Repatha generated $870 million, up 44% year-over-year, exceeding the estimate of $812 million [4] - Prolia revenues were $1.05 billion, down 10% year-over-year but still beating the estimate of $975 million [5] - Xgeva revenues fell 20% year-over-year to $447 million, missing the estimate of $454 million [8] - Blincyto sales were $413 million, an 8% increase year-over-year, but missed the estimate of $435 million [9] - Otezla sales were $625 million, flat year-over-year, beating the estimate of $621 million [9] - Enbrel revenues declined 48% year-over-year to $532 million, missing the estimate of $636 million [10] - Tezspire recorded sales of $474 million, a 60% increase year-over-year, exceeding the estimate of $421 million [10] Cost and Margin Analysis - Adjusted operating margin decreased by 3.5 percentage points to 42.8% in Q4 [14] - Adjusted operating expenses rose 16% to $5.86 billion, with R&D expenses increasing by 26% to $2.13 billion [14] Full-Year Results - For the full year 2025, sales rose 10% to $36.8 billion, beating the estimate of $36.4 billion [15] - Adjusted earnings for 2025 were $21.84 per share, a 10% increase year-over-year, surpassing the estimate of $21.29 per share [15] 2026 Guidance - Amgen expects total revenues in the range of $37.0 billion to $38.4 billion for 2026, with adjusted earnings projected between $21.60 and $23.00 per share [17] - Adjusted operating margin is anticipated to be approximately 45% to 46% for 2026 [17] Pipeline Developments - Amgen is advancing MariTide, a GIPR/GLP-1 receptor, with six phase III obesity studies underway [19][20] - Enrollment has been completed in two pivotal studies for MariTide, with ongoing studies for cardiovascular disease and heart failure [21] - Plans to initiate phase III studies for MariTide in type II diabetes are set for later in 2026 [22]

Key Takeaways FDA granted priority review to AZN's Datroway sBLA for unresectable or metastatic TNBC, with a Q2 2026 target.AZN's Datroway already has approvals in breast and lung cancer and is being studied across multiple cancers.The FDA issued a CRL for AZN's Saphnelo SC. AZN has resubmitted data and expects a U.S. decision in H1 2026.AstraZeneca (AZN) and its Japan-based partner Daiichi Sankyo announced that the FDA has accepted and granted priority review to their supplemental biologics license applica ...

Market Overview - US stocks exhibited mixed performance as Wall Street evaluated a new wave of earnings while awaiting Alphabet's results, with a notable shift from tech stocks to blue-chip names [1] - The Dow Jones Industrial Average rose approximately 0.6%, while the S&P 500 decreased by 0.3%, and the Nasdaq Composite fell over 1% [1] AI Impact on Stocks - Wall Street is grappling with fears of AI disruption, leading to a significant sell-off in software stocks that affected global markets, including Europe and Asia [2] - The broader pessimism surrounding AI has prompted a rotation from high-profile tech stocks to value stocks, negatively impacting companies like Nvidia and Microsoft [2] Upcoming Earnings Reports - Attention is focused on the upcoming earnings results from Alphabet and Arm Holdings, particularly regarding AI demand, followed by Amazon's quarterly report [3] Earnings Expectations - JPMorgan indicated that even strong earnings reports may not suffice to reassure the market unless companies can demonstrate that AI will act as a tailwind rather than a headwind [4] - Advanced Micro Devices experienced a sharp decline in shares due to a weak sales outlook, raising concerns about its competitiveness against Nvidia in the AI sector [4] Labor Market Insights - An ADP report revealed that employers added only 22,000 jobs in January, significantly below the expected 45,000, highlighting potential weaknesses in the labor market [5] Pharmaceutical Sector Performance - Eli Lilly's stock surged following a positive profit forecast for 2026, driven by increased demand for its weight-loss drugs [6] - Conversely, shares of Novo Nordisk plummeted after the company projected a significant decline in sales, surprising investors [6]

Financial Data and Key Metrics Changes - In 2025, full-year revenue grew by 45% to $65.2 billion compared to 2024, with earnings per share increasing by 86% to $24.21 [6][10] - Q4 revenue increased by 43% compared to Q4 2024, with gross margin at 83.2%, consistent with Q4 2024 [10][11] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [10] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [12] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% share of total prescriptions, generating $109 million in revenue [12] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [14] Market Data and Key Metrics Changes - U.S. revenue increased by 43% in Q4, driven by volume growth of Mounjaro and Zepbound, partially offset by a 7% decline in price [11] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [11] Company Strategy and Development Direction - The company executed 39 business development transactions and is investing in artificial intelligence for drug discovery [7] - Plans to build multiple new manufacturing sites in the U.S. and Europe to expand manufacturing capacity [7] - The company anticipates launching Orforglipron for chronic weight management in the U.S. in Q2 2026, with a focus on expanding the addressable market [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the incretin analog market and expects continued robust growth in 2026 [16] - The company is preparing for potential challenges in Medicaid access but anticipates new states will add coverage in 2027 [17] - Management highlighted the importance of patient satisfaction and real-world efficacy for new product launches [42] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [8] - The company has one of the largest clinical stage pipelines in its history, with 36 active phase III programs [18] Q&A Session Summary Question: Metrics for Orforglipron launch - Management indicated they will track market expansion and patient satisfaction as key success factors for Orforglipron [41][43] Question: Accelerated pathways for international approvals - Management expects most international launches for Orforglipron to occur in late 2026 to 2027, with some exceptions [47] Question: International Mounjaro growth - Management noted Q4 as a strong base for 2026 growth, with a focus on market expansion and reimbursement strategies [53][54] Question: Investment in immunology - Management is reinvesting proceeds from obesity opportunities to accelerate growth in immunology and other areas [60] Question: Medicare volume ramp and employer opt-ins - Management expects Medicare access to be granted by July 1, 2026, and anticipates a bolus of patients moving into the Medicare space [65][66] Question: Combo therapies with Zepbound - Management sees significant opportunities in combination therapies for immune diseases and is pursuing various studies [75]

Financial Data and Key Metrics Changes - In 2025, Eli Lilly's full-year revenue reached $65.2 billion, a 45% increase compared to 2024, with earnings per share growing by 86% to $24.21 [10][5] - Q4 revenue grew 43% compared to Q4 2024, with a gross margin of 83.2%, consistent with Q4 2024 [10][11] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [10] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [12] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% market share, generating $109 million in revenue [12] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [15] Market Data and Key Metrics Changes - U.S. revenue increased 43% in Q4, driven by volume growth of Mounjaro and Zepbound, partially offset by a 7% decline in price [11] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [11][12] Company Strategy and Development Direction - The company executed 39 business development transactions and is investing in AI to enhance drug discovery [7] - Plans to build multiple new manufacturing sites in the U.S. and Europe to expand production capacity [7] - The company aims to launch Orforglipron for chronic weight management in the U.S. in Q2 2026, with expectations for significant market expansion [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the incretin analog market, anticipating continued robust growth in 2026 [17] - The company expects revenue to be between $80 billion and $83 billion in 2026, a 25% increase compared to 2025 [16] - Management acknowledged potential pricing pressures but believes volume growth will offset these challenges over time [17] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [8] - The number of patients engaging with Lilly Direct increased to over 1 million in 2025 [8] Q&A Session Summary Question: Metrics for Orforglipron Launch - Management discussed tracking market expansion and patient satisfaction as key metrics for Orforglipron's success [39][41] Question: Accelerated Approval Pathways for Orforglipron - Management indicated that most international launches for Orforglipron are expected in late 2026 to 2027, with some exceptions [45][47] Question: International Mounjaro Growth - Management noted that Q4 serves as a base for 2026 growth, with a focus on market expansion and reimbursement strategies [50][53] Question: Investment in Immunology - Management highlighted ongoing investments in immunology and the potential for combination therapies to enhance treatment outcomes [56][59] Question: Medicare Volume Ramp Impact - Management expects Medicare access to significantly impact volume growth starting July 1, 2026, with a bolus of patients transitioning to Medicare [62][64]

Financial Data and Key Metrics Changes - In 2025, full-year revenue reached $65.2 billion, a 45% increase compared to 2024, with earnings per share growing by 86% to $24.21 [4][8] - Q4 revenue grew 43% compared to Q4 2024, with gross margin at 83.2%, consistent with Q4 2024 [8][9] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [8] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [10] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% market share, generating $109 million in revenue [10] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [12] Market Data and Key Metrics Changes - U.S. revenue increased 43% in Q4, driven by volume growth of Mounjaro and Zepbound, despite a 7% decline in price [9] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [9][10] Company Strategy and Development Direction - The company executed 39 business development transactions and expanded its manufacturing footprint, committing over $55 billion since 2020 [5][6] - Plans to launch Orforglipron for chronic weight management in the U.S. in Q2 2026, with expectations for significant market expansion [15][16] - The company aims to leverage AI for drug discovery and has partnered with NVIDIA to enhance its capabilities [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory in the U.S. incretin analogs market and anticipated continued robust growth in 2026 [15] - The company expects revenue between $80 billion and $83 billion in 2026, a 25% increase from 2025, despite anticipated pricing pressures [13][16] - Management highlighted the importance of expanding access to obesity medications through Medicare and Medicaid [6][16] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [6] - The leadership team was strengthened with the addition of two new executives [7] Q&A Session Summary Question: Metrics for Orforglipron's Launch - Management indicated they would track market expansion and patient satisfaction as key metrics for Orforglipron's success [39][40] Question: Accelerated Approval Pathways for Orforglipron - Management expects most international launches for Orforglipron to occur in late 2026 and 2027, with some exceptions [44] Question: International Mounjaro Growth - Management noted that Q4 served as a strong base for 2026 growth, with a focus on market expansion and reimbursement strategies [50] Question: Investment in Immunology - Management emphasized ongoing investments in immunology and the potential for combination therapies to enhance treatment outcomes [56] Question: Medicare Volume Ramp Impact - Management expects a significant number of patients to transition to Medicare, which will positively impact revenue growth [62][63] Question: Combination Therapies with Zepbound - Management is exploring various combination therapies to address immune diseases and obesity, with ongoing trials expected to yield promising results [71][72] Question: Pricing Dynamics in the Incretin Portfolio - Management discussed ongoing discussions with PBMs to expand access and the importance of affordability in driving utilization [76] Question: Importance of Obesity-Related Indications - Management sees growing evidence supporting the coverage of obesity medications for various comorbidities, which could enhance long-term market opportunities [82]

WARNING The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. DIZAL PHARMACEUTICAL CO., LTD. 迪哲（江蘇）醫藥股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability ...

Core Viewpoint - Terns Pharmaceuticals, Inc. (TERN) shows potential for significant upside, with a mean price target of $58.13 indicating a 50.9% increase from its current price of $38.52 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets, with a standard deviation of $5.19, indicating variability among analysts [2] - The lowest estimate is $54.00, suggesting a 40.2% increase, while the highest estimate is $70.00, indicating an 81.7% potential surge [2] - Analysts' price targets should be approached with caution, as they may not always accurately reflect future stock movements [3][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TERN's earnings prospects, with a consensus indicating better-than-previously estimated earnings [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 5.5% rise in the Zacks Consensus Estimate for the current year [12] - TERN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Implications of Price Target Clustering - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction [9] - While price targets can provide a starting point for further research, they should not be the sole basis for investment decisions [10][14]

Core Viewpoint - Novo Nordisk A/S is experiencing significant stock declines due to a weak sales forecast despite beating fourth-quarter earnings and revenue estimates, with the company citing "unprecedented" price pressures from competition in the weight-loss drug market and potential drug cost cuts by President Trump [1] Group 1: Stock Performance - Novo Nordisk's stock is down 3.7% to $48.44, extending a previous 14.6% decline, and is now at its lowest levels since December [1][2] - The stock has decreased by 41.4% year over year [2] Group 2: Market Activity - Options trading shows increased bullish sentiment, with 56,000 calls exchanged today, which is double the typical volume, compared to 27,000 puts [2] - The March 45 put is noted as the most active contract [2] Group 3: Options Trading Trends - Over the past 10 weeks, calls have been more popular than usual, with a 50-day call/put volume ratio of 4.59, ranking higher than 97% of readings from the past year [3] - Novo Nordisk stock has historically outperformed options traders' volatility expectations, reflected in a Schaeffer's Volatility Scorecard (SVS) of 89 out of 100 [3]